New vaccine aims to stop multiple myeloma from coming back
NCT ID NCT06435910
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a personalized dendritic cell vaccine in 10 multiple myeloma patients who are already in very good remission. The vaccine is designed to train the immune system to keep the cancer from returning. The main goal is to see if the vaccine is safe, with a secondary look at whether it helps maintain remission.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dendritic cell vaccine
- What this could lead to
- If it works, this could help multiple myeloma patients stay in remission longer after standard treatment.
- What could go wrong
- This is a very early Phase 1 trial with only 10 participants, so it is too soon to know if it works. The main goal is safety, not effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA OR PLASMACYTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.